User menu

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

Bibliographic reference Machiels, Jean-Pascal ; Staddon, Arthur ; Herremans, Catherine ; Keung, Chi ; Bernard, Apexa ; et. al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. In: Cancer Chemotherapy and Pharmacology, Vol. 74, no. 4, p. 729-737 (2014)
Permanent URL http://hdl.handle.net/2078.1/147212
  1. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth G.T, D'Incalci M, Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action, 10.1016/s0959-8049(00)00357-9
  2. Takebayashi Yuji, Pourquier Philippe, Zimonjic Drazen B., Nakayama Kentaro, Emmert Steffen, Ueda Takahiro, Urasaki Yoshimasa, Kanzaki Atsuko, Akiyama Shin-ichi, Popescu Nicholas, Kraemer Kenneth H., Pommier Yves, 10.1038/91008
  3. EMA Yondelis (2012) EPAR summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000773/WC500045833.pdf . Accessed 12 Aug 2013
  4. Perez-Ruixo Juan Jose, Zannikos Peter, Hirankarn Sarapee, Stuyckens Kim, Ludwig Elizabeth A, Soto-Matos Arturo, Lopez-Lazaro Luis, Owen Joel S, Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743,??Yondelis??) in Cancer Patients : , 10.2165/00003088-200746100-00005
  5. Beumer Jan, Lopez-Lazaro L., Schellens Jan, Beijnen Jos, Tellingen Olaf, Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743), 10.2174/157488409787236047
  6. Chuk M. K., Balis F. M., Fox E., Trabectedin, 10.1634/theoncologist.2009-0104
  7. Guidance for Industry (2012) Drug interaction studies—Study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf . Accessed 10 Sept 2013
  8. Kerbusch T, Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin, 10.1067/mcp.2001.117283
  9. Lassen U., Miller W. H., Hotte S., Evans T. R. J., Kollmansberger C., Adamson D., Nielsen D. L., Spicer J., Chen E., Meyer T., Brown K., Rafi R., Sawyer M. B., Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours, 10.1007/s00280-012-2038-0
  10. Chu Q., Mita A., Forouzesh B., Tolcher A. W., Schwartz G., Nieto A., Soto-Matos A., Alfaro V., Lebedinsky C., Rowinsky E. K., Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors, 10.1158/1078-0432.ccr-10-0062
  11. Forouzesh B., Hidalgo M., Chu Q., Mita A., Mita M., Schwartz G., Jimeno J., Gomez J., Alfaro V., Lebedinsky C., Zintl P., Rowinsky E. K., Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies, 10.1158/1078-0432.ccr-08-2889
  12. von Mehren M., Schilder R. J., Cheng J. D., Temmer E., Cardoso T. M., Renshaw F. G., Bayever E., Zannikos P., Yuan Z., Cohen R. B., A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies, 10.1093/annonc/mdn363
  13. Martin-Liberal Juan, Judson Ian, Safety evaluation of trabectedin in treatment of soft-tissue sarcomas, 10.1517/14740338.2013.829037
  14. Sessa Cristiana, Del Conte Gianluca, Christinat Alexandre, Cresta Sara, Perotti Antonella, Gallerani Elisa, Lardelli Pilar, Kahatt Carmen, Alfaro Vicente, Iglesias Jorge L., Fernández-Teruel Carlos, Gianni Luca, Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors, 10.1007/s10637-013-9942-y
  15. Thertulien R., Manikhas G. M., Dirix L. Y., Vermorken J. B., Park K., Jain M. M., Jiao J. J., Natarajan J., Parekh T., Zannikos P., Staddon A. P., Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies, 10.1007/s00280-011-1697-6